This systematic overview of antimalarial drug development addresses current challenges and opportunities and presents numerous case studies for the successful development of effective novel antimalarials.
This systematic overview of antimalarial drug development addresses current challenges and opportunities and presents numerous case studies for the successful development of effective novel antimalarials.
Pravin Kendrekar studied chemistry at Swami Ramanand Teerth Marathwada University (India) and completed his Ph.D. in Organic Chemistry at Nagoya University of Technology (Japan). After post-doctoral work at Ben Gurion University (Israel) and the University of the Free State (South Africa), he joined the Central University of Technology at Bloemfontein (South Africa) in 2017, where he is currently a group leader in the Unit for Drug Discovery Research. The primary focus of his work is in antimalarial therapy.
Inhaltsangabe
INTRODUCTION Past, Present and Future Drug Development for Malaria
CHALLENGES AND OPPORTUNITIES IN MALARIA THERAPY Scientific Challenges and Treatment Opportunities in the Face of Shifting Malaria Epidemiology Emerging Formulation Technologies against Malaria Resurgence Targeted Drug Delivery for Malarial Therapy The Imminent Threat of Antimalarial Drug Resistance Current Therapies and New Drug Targets for the Future Drug Development of Drug Resistant Malaria
DRUG DEVELOPMENT Assays for Antimalarial Drug Discovery Aminoacyl-tRNA Synthetases as Malarial Drug Targets: A Structural Biology Perspective Natural Products as a Source for Antimalarial Drug Development Process - An Overview Mushroom-Derived Products as an Alternative Antimalarial Therapeutics: A Review Discovery and Trends of 8-Aminoquinoline and 4-Aminoquinoline Classes of Antimalarials Antimalarial Activity of Novel Class of 1,3-Benzoxaborole Derivatives Containing 1, 3, 4-Oxadiazole Moiety
VACCINE PERSPECTIVE Recent Advances in Malaria Vaccine Development Toll-Like Receptor-Based Adjuvants - A Gateway Towards Improved Malaria Vaccination Pure TLR7 Agonistic BBIQ is a Potential Adjuvant against P. Berghei ANKA Challenge in Vivo
INTRODUCTION Past, Present and Future Drug Development for Malaria
CHALLENGES AND OPPORTUNITIES IN MALARIA THERAPY Scientific Challenges and Treatment Opportunities in the Face of Shifting Malaria Epidemiology Emerging Formulation Technologies against Malaria Resurgence Targeted Drug Delivery for Malarial Therapy The Imminent Threat of Antimalarial Drug Resistance Current Therapies and New Drug Targets for the Future Drug Development of Drug Resistant Malaria
DRUG DEVELOPMENT Assays for Antimalarial Drug Discovery Aminoacyl-tRNA Synthetases as Malarial Drug Targets: A Structural Biology Perspective Natural Products as a Source for Antimalarial Drug Development Process - An Overview Mushroom-Derived Products as an Alternative Antimalarial Therapeutics: A Review Discovery and Trends of 8-Aminoquinoline and 4-Aminoquinoline Classes of Antimalarials Antimalarial Activity of Novel Class of 1,3-Benzoxaborole Derivatives Containing 1, 3, 4-Oxadiazole Moiety
VACCINE PERSPECTIVE Recent Advances in Malaria Vaccine Development Toll-Like Receptor-Based Adjuvants - A Gateway Towards Improved Malaria Vaccination Pure TLR7 Agonistic BBIQ is a Potential Adjuvant against P. Berghei ANKA Challenge in Vivo
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
